{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:48Z","timestamp":1790794788118,"version":"4.1.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that enables tumor development. One of the mechanisms of immune evasion used by MM cells is the inhibition of natural killer (NK) cell effector functions; thus, the restoration of NK cell antitumor activity represents a key goal to increase tumor cell recognition, avoid tumor escape and potentially enhancing the effect of other drugs. In this study, we evaluated the ability of the investigational medicine NKTR-255, an IL-15 receptor agonist, to engage the IL-15 pathway and stimulate NK cells against MM cells. We observed that incubation with NKTR-255 was able to tilt the balance toward an activated phenotype in NK cells isolated from peripheral blood mononuclear cells of patients with MM, with increased expression of activating receptors on the surface of treated NK cells. This resulted in an enhanced degranulation, cytokine release, and anti-tumor cytotoxicity when the NK cells were exposed to both MM cell lines and primary MM cells. We further evaluated the in\u00a0vivo effect of NKTR-255 in fully humanized immunocompetent mice subcutaneously engrafted with H929 MM cells. Compared with placebo, weekly injection of the mice with NKTR-255 increased the number of circulating NK cells in peripheral blood and delayed tumor growth. Finally, we observed that combination of NKTR-255 with the anti-CD38 antibody, daratumumab, was effective against MM cells in\u00a0vitro and in\u00a0vivo. Taken together, our data suggest a significant impact of NKTR-255 in inducing NK cell function against MM cells with important translational implications.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007985","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:55:40Z","timestamp":1658883340000},"page":"9-19","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-118X","authenticated-orcid":false,"given":"Rafael Alonso","family":"Fernandez","sequence":"first","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Department of Hematology, Hospital Universitario 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncol\u00f3gicas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Encinas","family":"Mayoral","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Department of Hematology, Hospital Universitario 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncol\u00f3gicas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Pierre-Louis","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidai","family":"Mu","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospital Universitario 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncol\u00f3gicas, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Oncolog\u00eda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Primo","sequence":"additional","affiliation":[{"name":"3Vivia Biotech, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-1521","authenticated-orcid":false,"given":"Takahiro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"4Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao","family":"Prabhala","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem W.","family":"Overwijk","sequence":"additional","affiliation":[{"name":"4Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023011817041865700_bib1","doi-asserted-by":"crossref","first-page":"e1486949","DOI":"10.1080\/2162402X.2018.1486949","article-title":"Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients","volume":"8","author":"Leone","year":"2018","journal-title":"OncoImmunology"},{"issue":"3","key":"2023011817041865700_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12307-011-0086-3","article-title":"The immune microenvironment of myeloma","volume":"4","author":"Noonan","year":"2011","journal-title":"Cancer Microenviron"},{"issue":"3","key":"2023011817041865700_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br J Haematol"},{"issue":"7","key":"2023011817041865700_bib4","first-page":"997","article-title":"High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment","volume":"8","author":"Solimando","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"2023011817041865700_bib5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"2023011817041865700_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-40320-5_12","article-title":"Role of the immune response in disease progression and therapy in multiple myeloma","volume":"169","author":"Lee","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2023011817041865700_bib7","doi-asserted-by":"crossref","first-page":"198539","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed Res Int"},{"issue":"1","key":"2023011817041865700_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023011817041865700_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","article-title":"Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma","volume":"144","author":"Brimnes","year":"2006","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2023011817041865700_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"issue":"15","key":"2023011817041865700_bib11","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2023011817041865700_bib12","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/leu.2012.113","article-title":"Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2023011817041865700_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2023011817041865700_bib14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2023011817041865700_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med Oncol"},{"issue":"18","key":"2023011817041865700_bib16","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"2023011817041865700_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2023011817041865700_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/cei.12196","article-title":"Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy","volume":"175","author":"Chan","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2023011817041865700_bib19","doi-asserted-by":"crossref","first-page":"816499","DOI":"10.3389\/fimmu.2021.816499","article-title":"Natural killer cells in the malignant niche of multiple myeloma","volume":"12","author":"Venglar","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2023011817041865700_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2018","journal-title":"Br J Cancer"},{"issue":"24","key":"2023011817041865700_bib21","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","article-title":"IL15 and T-cell stemness in T-cell\u2013based cancer immunotherapy","volume":"75","author":"Pilipow","year":"2015","journal-title":"Cancer Res"},{"key":"2023011817041865700_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fimmu.2017.00930","article-title":"Developmental and functional control of natural killer cells by cytokines","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"2023011817041865700_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2023011817041865700_bib24","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.4049\/jimmunol.1700046","article-title":"Cutting edge: differential fine-tuning of IL-2- and IL-15-dependent functions by targeting their common IL-2\/15R\u03b2\/\u03b3c receptor","volume":"198","author":"Meghnem","year":"2017","journal-title":"J\u00a0Immunol"},{"issue":"14","key":"2023011817041865700_bib25","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/cancers13143534","article-title":"IL-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2023011817041865700_bib26","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023011817041865700_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-12-2143","article-title":"Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T\u00a0cell-based therapies for lymphoma","volume":"19","author":"Perna","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023011817041865700_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Steel","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"2023011817041865700_bib29","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"key":"2023011817041865700_bib30","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.3389\/fimmu.2018.02743","article-title":"Enhancing the activation and releasing the brakes: a double hit strategy to improve NK cell cytotoxicity against multiple myeloma","volume":"9","author":"Tognarelli","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"2023011817041865700_bib31","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"2023011817041865700_bib32","doi-asserted-by":"crossref","first-page":"e1237327","DOI":"10.1080\/2162402X.2016.1237327","article-title":"IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay","volume":"5","author":"Weng","year":"2016","journal-title":"OncoImmunology"},{"issue":"8","key":"2023011817041865700_bib33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023011817041865700_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2023011817041865700_bib35","doi-asserted-by":"crossref","first-page":"18093","DOI":"10.1074\/jbc.M113.461756","article-title":"Characterization and favorable in\u00a0vivo properties of heterodimeric soluble IL-15\u00b7IL-15R\u03b1 cytokine compared to IL-15 monomer","volume":"288","author":"Chertova","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"2023011817041865700_bib36","doi-asserted-by":"crossref","first-page":"e002024","DOI":"10.1136\/jitc-2020-002024","article-title":"NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"19","key":"2023011817041865700_bib37","doi-asserted-by":"crossref","first-page":"e144365","DOI":"10.1172\/JCI144365","article-title":"NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells","volume":"131","author":"Robinson","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"suppl 1","key":"2023011817041865700_bib38","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2018-99-115638","article-title":"Pharmacokinetic and pharmacodynamic study of NKTR-255, a polymer-conjugated human IL-15, in cynomolgus monkey","volume":"132","author":"Miyazaki","year":"2018","journal-title":"Blood"},{"issue":"13 suppl","key":"2023011817041865700_bib39","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1538-7445.AM2017-1603","article-title":"Abstract 1603: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation","volume":"77","author":"Kuo","year":"2017","journal-title":"Cancer Res"},{"issue":"27","key":"2023011817041865700_bib40","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.2217\/fon-2021-0576","article-title":"Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies","volume":"17","author":"Shah","year":"2021","journal-title":"Future Oncol"},{"key":"2023011817041865700_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4939-8885-3_8","article-title":"A\u00a0flow cytometric NK cell-mediated cytotoxicity assay to evaluate anticancer immune responses in\u00a0vitro","volume":"1884","author":"Lorenzo-Herrero","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2023011817041865700_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clml.2013.11.006","article-title":"Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine","volume":"14","author":"Bennett","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023011817041865700_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.10.004","article-title":"IL-15 signaling in NK cell cancer immunotherapy","volume":"44","author":"Rautela","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"46","key":"2023011817041865700_bib44","doi-asserted-by":"crossref","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2023011817041865700_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2023011817041865700_bib46","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.bpj.2010.07.061","article-title":"Activation or tolerance of natural killer cells is modulated by ligand quality in a nonmonotonic manner","volume":"99","author":"Das","year":"2010","journal-title":"Biophys J"},{"issue":"12","key":"2023011817041865700_bib47","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2023011817041865700_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","article-title":"CD57 in human natural killer cells and T-lymphocytes","volume":"65","author":"Kared","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2023011817041865700_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2013.00422","article-title":"Functional significance of CD57 expression on human NK cells and relevance to disease","volume":"4","author":"Nielsen","year":"2013","journal-title":"Front Immunol"},{"issue":"2","key":"2023011817041865700_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1078\/0171-2985-00219","article-title":"Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells","volume":"207","author":"Clausen","year":"2003","journal-title":"Immunobiology"},{"issue":"11","key":"2023011817041865700_bib51","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V106.11.3322.3322","article-title":"CD69 is required for activated NK cell-mediated killing of resistant targets","volume":"106","author":"Marden","year":"2005","journal-title":"Blood"},{"issue":"14","key":"2023011817041865700_bib52","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"21","key":"2023011817041865700_bib53","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1158\/0008-5472.CAN-04-1860","article-title":"Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2","volume":"64","author":"Roychowdhury","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"2023011817041865700_bib54","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"2023011817041865700_bib55","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2217\/imt.11.102","article-title":"NK cells: immune cross-talk and therapeutic implications","volume":"3","author":"Malhotra","year":"2011","journal-title":"Immunotherapy"},{"issue":"9","key":"2023011817041865700_bib56","doi-asserted-by":"crossref","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"OncoImmunology"},{"issue":"6","key":"2023011817041865700_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00262-009-0807-3","article-title":"Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked","volume":"59","author":"von Lilienfeld-Toal","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2023011817041865700_bib58","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2023011817041865700_bib59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imm.12082","article-title":"Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"issue":"4","key":"2023011817041865700_bib60","first-page":"297","article-title":"Dendritic cell counts and their subsets during treatment of multiple myeloma","volume":"54","author":"Kovarova","year":"2007","journal-title":"Neoplasma"},{"issue":"1","key":"2023011817041865700_bib61","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.1998.00525.x","article-title":"B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors","volume":"100","author":"Rawstron","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"2023011817041865700_bib62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.180.4.1395","article-title":"Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor","volume":"180","author":"Carson","year":"1994","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"2023011817041865700_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.exphem.2007.08.012","article-title":"NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma","volume":"36","author":"Moga","year":"2008","journal-title":"Exp Hematol"},{"issue":"23","key":"2023011817041865700_bib64","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"issue":"16","key":"2023011817041865700_bib65","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex\u00a0vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023011817041865700_bib66","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2023011817041865700_bib67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2023011817041865700_bib68","doi-asserted-by":"crossref","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/1\/9\/2029409\/blooda_adv-2022-007985-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/1\/9\/2029409\/blooda_adv-2022-007985-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T17:06:44Z","timestamp":1674061604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/1\/9\/486019\/Improving-NK-cell-function-in-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007985","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}